Now enrolling patients in the global Phase 3 CoMpass trial to evaluate the safety and efficacy of belzupacap sarotalocan (bel-sar) for the first-line treatment of adult patients with small choroidal melanoma or indeterminate lesions.
Scientific Advisors

Scientific Founder
John T. Schiller, PhD
Scientific Founder

Ocular Oncology
Carol L. Shields, MD
Advisor
Evangelos Gragoudas, MD
Advisor
Arun D. Singh
Advisor
Jay S. Duker, MD
Advisor
Brian Marr, MD
Advisor
Richard Carvajal, MD
Advisor

Urologic Oncology
Andrea Apolo, MD
Advisor
Max Kates, MD
Advisor
Isaac Kim, MD, PhD, MBA
Advisor
Seth P. Lerner, MD
Advisor
Neal Shore, MD, FACS
Advisor
Gary Steinberg, MD
Advisor